Treatment options include contact lenses, intrastromal corneal ring segments, custom topography-guided transepithelial PRK combined with corneal collagen cross-linking, or corneal transplant. When cross-linking is performed only after the cornea becomes distorted, vision remains blurry even though the disease is stabilised. As a result, combining corneal collagen cross-linking with<unk>  <unk>  Xtra') aims to strengthen the cornea at the point of surgery and may be useful in cases where a very thin cornea is expected after the<unk>  procedure. This would include cases of high spectacle power and people with thin corneas before surgery. Definitive evidence that the procedure can reduce the risk of corneal<unk>  will only become available a number of years later as corneal<unk> , if it happens, usually occurs in the late<unk> -operative period. Some study show that combining<unk>  with cross-linking adds refractive stability to hyperopic treatments and may also do the same for very high myopic treatments. In 2016, the FDA approved the KXL system and two photoenhancers for the treatment of corneal<unk>  following refractive surgery.
Post-LASIK ectasia
Apudoma
Chorangioma
Rhinoscleroma
Fundic gland polyposis
Traumatic anserine folliculosis
Fundic gland polyp
Canalicular adenoma